Caris Life Sciences (CAI) Change in Account Payables (2024 - 2026)

Caris Life Sciences' Change in Account Payables history runs 3 years deep, the most recent figure standing at $16.4 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 1041.4% year-over-year to $16.4 million in Q1 2026; TTM through Mar 2026 was $29.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $11.0 million, up 4982.74% from the prior year.
• Change in Account Payables improved to $16.4 million in Q1 2026 per CAI's latest filing, from $12.2 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $16.4 million in Q1 2026 and bottomed at -$5.3 million in Q4 2024.
• The 3-year median for Change in Account Payables is $729000.0 (2025), against an average of $3.5 million.
• Across the five-year window, Change in Account Payables slumped 70.01% in 2025 and surged 1041.4% in 2026, its largest moves.
• Year by year, Change in Account Payables stood at -$5.3 million in 2024, then jumped by 331.65% to $12.2 million in 2025, then surged by 33.85% to $16.4 million in 2026.
• Per Business Quant, the three latest CAI Change in Account Payables figures stand at $16.4 million (Q1 2026), $12.2 million (Q4 2025), and $729000.0 (Q3 2025).